Biotech Values

[DewDiligence]

Well, I thought the bottommost paragraph was the most consequential because it contained a quote from a division director at the FDA (rather than the self-serving comments of a biotech CEO):

“I don’t see any show stoppers for these kinds of products,” says Basil Golding, director of the division of Hematology at FDA’s Center for Biologics Evaluation and Research. “Provided good manufacturing practices are followed, the products would be approved if the studies met certain requirements of safety and efficacy.”